​

ImageneBio Stock (NASDAQ:IMA)

ForecastOwnershipFinancialsChart
ImageneBio by TradingView

Previous Close

$7.12

52W Range

$5.70 - $19.20

50D Avg

$6.78

200D Avg

$11.30

Market Cap

$82.19M

Avg Vol (3M)

$49.34K

Beta

0.44

Div Yield

-

IMA Company Profile

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

10

IPO Date

Feb 27, 1998

Website

IMA Performance

IMA Financial Summary

Dec 24Dec 23Dec 22
Revenue-$9.16M$15.62M
Operating Income$-58.97M$-75.42M$-70.90M
Net Income$-49.23M$-68.17M$-68.77M
EBITDA$-48.59M$-74.40M$-70.15M
Basic EPS$-1.02$-1.63$-1.90
Diluted EPS$-1.02$-1.63$-1.90

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
KLRSKalaris Therapeutics Inc
QNCXQuince Therapeutics, Inc.
ARTVArtiva Biotherapeutics, Inc.
MGXMetagenomi, Inc. Common Stock
IFRXInflaRx N.V.
STROSutro Biopharma, Inc.
CNTXContext Therapeutics Inc.
OVIDOvid Therapeutics Inc.
CNTBConnect Biopharma Holdings Limited
STTKShattuck Labs, Inc.